Page 28 - லிவர்பூல் பள்ளி ஆஃப் வெப்பமண்டல மருந்து News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Vir Biotechnology and GSK Announce NHS-Supported AGILE Study to Evaluate VIR-7832 in the Early Treatment of COVID-19 Second monoclonal antibody from Vir-GSK collaboration to be investigated as a potential COVID-19 treatment Preclinical data suggest VIR-7832 has two distinguishing properties: enhanced ability to clear infected cells and potential to enhance virus-specific T cell function, which could help treat and/or prevent COVID-19 infection Trial targeted to begin in 1Q:2021 at multiple sites across the UK SAN FRANCISCO and LONDON, Jan. 12, 2021 (GLOBE NEWSWIRE) Vir Biotechnology, Inc. (Nasdaq: VIR) and GlaxoSmithKline plc (LSE/NYSE: GSK) today announced an agreement with the U.K.-based AGILE initiative to evaluate VIR-7832 in patients with mild to moderate COVID-19 in a Phase 1b/2a clinical trial. VIR-7832 is a neutralizing COVID-19 antibody that preclinical data suggests has two distinguishing properties: an enhanced ability to clear infected cells and the potential to enh

United kingdomUnited statesCity ofUnited kingdom generalSarah elton farrKathleen quinnJeff mclaughlinSimon steelSonya ghobrialDanielle smithNeera ravindranTim foleyJames dodwellCara millerHal barronKristen neese